Bernard J. Zovighian - May 3, 2022 Form 3 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, TMTT
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
May 3, 2022
Transactions value $
$0
Form type
3
Date filed
5/4/2022, 09:51 PM
Next filing
May 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EW Common Stock 37.4K May 3, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EW Employee Stock Option (Right to Acquire) May 3, 2022 Common Stock 14.9K $45.28 Direct F1
holding EW Employee Stock Option (Right to Acquire) May 3, 2022 Common Stock 50.7K $59.26 Direct F2
holding EW Employee Stock Option (Right to Acquire) May 3, 2022 Common Stock 46.2K $72.68 Direct F3
holding EW Employee Stock Option (Right to Acquire) May 3, 2022 Common Stock 37.4K $93.10 Direct F4
holding EW Performance Rights May 3, 2022 Common Stock 5.35K $0.00 Direct F5
holding EW Performance Rights May 3, 2022 Common Stock 6.38K $0.00 Direct F6
holding EW Performance Rights May 3, 2022 Common Stock 7.2K $0.00 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F2 These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F3 These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F4 These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F5 Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.
F6 Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.
F7 Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

Remarks:

Exhibit 24, Power of Attorney, attached.